http://purl.org/np/RAxdaOwN6NX2MlsjOKq7wrfOb94EimJaEQMdpgm9OHEw4#Head http://purl.org/np/RAxdaOwN6NX2MlsjOKq7wrfOb94EimJaEQMdpgm9OHEw4 http://www.nanopub.org/nschema#hasAssertion http://purl.org/np/RAxdaOwN6NX2MlsjOKq7wrfOb94EimJaEQMdpgm9OHEw4#assertion http://purl.org/np/RAxdaOwN6NX2MlsjOKq7wrfOb94EimJaEQMdpgm9OHEw4 http://www.nanopub.org/nschema#hasProvenance http://purl.org/np/RAxdaOwN6NX2MlsjOKq7wrfOb94EimJaEQMdpgm9OHEw4#provenance http://purl.org/np/RAxdaOwN6NX2MlsjOKq7wrfOb94EimJaEQMdpgm9OHEw4 http://www.nanopub.org/nschema#hasPublicationInfo http://purl.org/np/RAxdaOwN6NX2MlsjOKq7wrfOb94EimJaEQMdpgm9OHEw4#pubinfo http://purl.org/np/RAxdaOwN6NX2MlsjOKq7wrfOb94EimJaEQMdpgm9OHEw4 http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.nanopub.org/nschema#Nanopublication http://purl.org/np/RAxdaOwN6NX2MlsjOKq7wrfOb94EimJaEQMdpgm9OHEw4#assertion http://purl.obolibrary.org/obo/DOID_7148 https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Disease http://purl.org/np/RAxdaOwN6NX2MlsjOKq7wrfOb94EimJaEQMdpgm9OHEw4#association http://www.w3.org/1999/02/22-rdf-syntax-ns#object http://purl.obolibrary.org/obo/DOID_7148 http://purl.org/np/RAxdaOwN6NX2MlsjOKq7wrfOb94EimJaEQMdpgm9OHEw4#association http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate https://w3id.org/biolink/vocab/treats http://purl.org/np/RAxdaOwN6NX2MlsjOKq7wrfOb94EimJaEQMdpgm9OHEw4#association http://www.w3.org/1999/02/22-rdf-syntax-ns#subject https://identifiers.org/drugbank:DB08895 http://purl.org/np/RAxdaOwN6NX2MlsjOKq7wrfOb94EimJaEQMdpgm9OHEw4#association http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement http://purl.org/np/RAxdaOwN6NX2MlsjOKq7wrfOb94EimJaEQMdpgm9OHEw4#association http://www.w3.org/2000/01/rdf-schema#label xeljanz xeljanz xr is a janus kinase jak inhibitor rheumatoid arthritis limitations of use 1 psoriatic arthritis limitations of use 1 ulcerative colitis limitations of use 1 rheumatoid arthritis xeljanz xeljanz xr is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to methotrexate it may be used as monotherapy or in combination with methotrexate or other nonbiologic disease modifying antirheumatic drugs dmards limitations of use use of xeljanz xeljanz xr in combination with biologic dmards or with potent immunosuppressants such as azathioprine and cyclosporine is not recommended psoriatic arthritis xeljanz xeljanz xr is indicated for the treatment of adult patients with active psoriatic arthritis who have had an inadequate response or intolerance to methotrexate or other disease modifying antirheumatic drugs dmards limitations of use use of xeljanz xeljanz xr in combination with biologic dmards or with potent immunosuppressants such as azathioprine and cyclosporine is not recommended ulcerative colitis xeljanz is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis uc limitations of use use of xeljanz in combination with biological therapies for uc or with potent immunosuppressants such as azathioprine and cyclosporine is not recommended http://purl.org/np/RAxdaOwN6NX2MlsjOKq7wrfOb94EimJaEQMdpgm9OHEw4#association https://w3id.org/biolink/vocab/association_type https://w3id.org/biolink/vocab/ChemicalToDiseaseOrPhenotypicFeatureAssociation http://purl.org/np/RAxdaOwN6NX2MlsjOKq7wrfOb94EimJaEQMdpgm9OHEw4#association https://w3id.org/biolink/vocab/provided_by https://w3id.org/um/NeuroDKG http://purl.org/np/RAxdaOwN6NX2MlsjOKq7wrfOb94EimJaEQMdpgm9OHEw4#association https://w3id.org/biolink/vocab/relation https://schema.org/TreatmentIndication https://identifiers.org/drugbank:DB08895 https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Drug http://purl.org/np/RAxdaOwN6NX2MlsjOKq7wrfOb94EimJaEQMdpgm9OHEw4#provenance http://purl.org/np/RAxdaOwN6NX2MlsjOKq7wrfOb94EimJaEQMdpgm9OHEw4#assertion http://www.w3.org/ns/prov#wasAttributedTo https://orcid.org/0000-0002-1468-3557 http://purl.org/np/RAxdaOwN6NX2MlsjOKq7wrfOb94EimJaEQMdpgm9OHEw4#pubinfo http://purl.org/np/RAxdaOwN6NX2MlsjOKq7wrfOb94EimJaEQMdpgm9OHEw4#sig http://purl.org/nanopub/x/hasAlgorithm RSA http://purl.org/np/RAxdaOwN6NX2MlsjOKq7wrfOb94EimJaEQMdpgm9OHEw4#sig http://purl.org/nanopub/x/hasPublicKey MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB http://purl.org/np/RAxdaOwN6NX2MlsjOKq7wrfOb94EimJaEQMdpgm9OHEw4#sig http://purl.org/nanopub/x/hasSignature JMe/DXRQeGZNv9fu1EXp2k0u5UBrXUb4STGw8AkfBSl7u8VeiPFv+g18jeriV0ELaFb6rfaTCoqgPk/QIaxt466NVpmuG1j4U+EuXf5X0JunaHZrMHgWdR2256HzyAtQBtDMayuapCht9EzeEmwDwatEv6SnfoZeOzc0sGVXgGM= http://purl.org/np/RAxdaOwN6NX2MlsjOKq7wrfOb94EimJaEQMdpgm9OHEw4#sig http://purl.org/nanopub/x/hasSignatureTarget http://purl.org/np/RAxdaOwN6NX2MlsjOKq7wrfOb94EimJaEQMdpgm9OHEw4 http://purl.org/np/RAxdaOwN6NX2MlsjOKq7wrfOb94EimJaEQMdpgm9OHEw4 http://purl.org/dc/terms/created 2021-07-03T14:28:19.986+02:00 http://purl.org/np/RAxdaOwN6NX2MlsjOKq7wrfOb94EimJaEQMdpgm9OHEw4 http://purl.org/dc/terms/creator https://orcid.org/0000-0002-1468-3557 http://purl.org/np/RAxdaOwN6NX2MlsjOKq7wrfOb94EimJaEQMdpgm9OHEw4 https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM http://purl.org/np/RAxdaOwN6NX2MlsjOKq7wrfOb94EimJaEQMdpgm9OHEw4 https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM http://purl.org/np/RAxdaOwN6NX2MlsjOKq7wrfOb94EimJaEQMdpgm9OHEw4 https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate http://purl.org/np/RAManV5GZI01JKzW_IPcfOXoiFTcZMmsV7qTCLkdzr4Gs